stockrowXenon Pharmaceuticals Inc.
XENE Healthcare Biotechnology
Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022.
- Revenue
- +100.7%
- EPS
- −3.74%
- Free cash flow
- −48.6%
Quarter to June 2026, against a year earlier
Follow XENE
Alert me
Xenon Pharmaceuticals Inc. (XENE) Return on assets
Xenon Pharmaceuticals Inc.'s return on assets over the twelve months to 30 June 2026 was −41.5%, up 6.8 percentage points from fiscal 2025 (−48.3%). Over the past ten years it has ranged from −54.1% (fiscal 2017) to −16.6% (fiscal 2020); the current reading is higher than 18% of that period. That is above the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −48.3% | (21.76) |
| FY2024 | −26.6% | (5.36) |
| FY2023 | −21.2% | (2.38) |
| FY2022 | −18.8% | 1.41 |
| FY2021 | −20.3% | (3.62) |
| FY2020 | −16.6% | 13.01 |
| FY2019 | −29.6% | 7.88 |
| FY2018 | −37.5% | 16.53 |
| FY2017 | −54.1% | (19.06) |
| FY2016 | −35.0% | (14.18) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | 23.2% |
| PBLS Parabilis Medicines, Inc. compare | 0.00% |
| ABCL AbCellera Biologics Inc. compare | −12.2% |
| TNGX Tango Therapeutics, Inc. compare | −18.9% |
| IOVA Iovance Biotherapeutics, Inc. compare | −23.3% |
| RLAY Relay Therapeutics, Inc. compare | −33.7% |
| IRON Disc Medicine, Inc. compare | −35.1% |
| XENE Xenon Pharmaceuticals Inc. | −41.5% |
| VKTX Viking Therapeutics, Inc. compare | −73.1% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on XENE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement